(Q54439463)

29 May 2018

title

Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. (English)

1 reference

29 May 2018

author

Georgina V. Long

1

1 reference

29 May 2018

Richard Scolyer

9

1 reference

29 May 2018

Richard F. Kefford

10

1 reference

29 May 2018

John F Thompson

7

John F Thompson

1 reference

29 May 2018

James S Wilmott

2

James S Wilmott

1 reference

29 May 2018

Lauren E Haydu

3

Lauren E Haydu

1 reference

29 May 2018

Julie R Howle

8

Julie Howle

1 reference

29 May 2018

Raghwa Sharma

5

Raghwa Sharma

1 reference

29 May 2018

Varsha Tembe

4

Varsha Tembe

1 reference

29 May 2018

author name string

Helen Rizos

6

1 reference

29 May 2018

publication date

3 May 2013

1 reference

29 May 2018

Pigment Cell & Melanoma Research

published in

1 reference

29 May 2018

volume

26

1 reference

29 May 2018

issue

4

1 reference

29 May 2018

page(s)

499-508

1 reference

29 May 2018

Expression of cell cycle regulators p21 and p27 as predictors of disease outcome in colorectal carcinoma.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Targeting BRAF for patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

CDK inhibitors: cell cycle regulators and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Genetic and morphologic features for melanoma classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Prognostic significance of cytoplasmic p27 expression in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Frequent mutations in the MITF pathway in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

MEK'ing the most of p53 reactivation therapy in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

BRAF targeted therapy changes the treatment paradigm in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

PDGF-BB regulates p27 expression through ERK-dependent RNA turn-over in vascular smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Improving melanoma classification by integrating genetic and morphologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12098

21 January 2018

Identifiers

DOI

10.1111/PCMR.12098

1 reference

29 May 2018

PubMed ID

23557327

1 reference

29 May 2018